Sana Biotechnology

### Executive Summary Sana Biotechnology raised $329M via Regulation D private placement, with first sale date of 2025-10-12. Backing from notable related persons Shield Capital and Founders Fund signals strong institutional confidence in synthetic biology and intracellular mRNA delivery. This is an initial Form D filing (not an amendment), indicating a fresh capital event. ### Investor Edge Sophisticated investors should monitor for an eventual D/A amendment that may disclose actual investors and terms — filing number 0001702600-24-20135. If this capital funds a manufacturing or partnership deal, it may signal a de-risking event before a future public listing. ### Sector capital positioning The $329M raise for a synthetic biology / mRNA delivery company flags sustained high-volume private capital flowing into next-gen therapeutics infrastructure. This amount is well above the typical early-stage round, suggesting a pre-IPO or major expansion capital event. ### Convergence Signals No direct public signals disclosed. However, the scale and related persons (venture firms) imply a potential near-term catalyst (e.g., clinical trial readout, manufacturing partnership, or IP filing). Watch for subsequent D/A amendments or public counterpart filings. ### Key Takeaways - Sana Biotechnology raised $329M in private placement, a very large round for synthetic biology/mRNA delivery. - Shield Capital and Founders Fund listed as related persons (likely directors or venture backers). - Initial Form D filing (no amendments) suggests a straightforward raise; future D/A filings may reveal more detail. ### Risk Indicators & Flags No immediate red flags; this is an initial Form D filing. However, the large raise in a private company without a public ticker limits transparency. Monitor for any subsequent D/A amendments that could indicate terms changes or reduced investor appetite. ### Verification & References Filing is available via SEC EDGAR at provided URL, accession 0001702600-24-20135. Data used: company Sana Biotechnology, $329M raised, Form D (initial), first sale 2025-10-12. Related persons listed are Shield Capital and Founders Fund; these are SEC-registered officers/directors per Form D instructions.